Skip to main content

GENTEX CORP

For the period ended Sep 30, 2025. Filed Nov 7, 2025.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2025 · Filed Nov 7, 2025

GNTX$19.42-0.4%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Unaudited Condensed Consolidated Statements of Shareholders' Investment

For the Three Months Ended September 30, 2025 and 2024

Common StockSharesCommon StockAmountAdditional Paid-InCapitalRetained EarningsAccumulated OtherComprehensiveIncome (Loss)TotalEquity Attributable to Noncontrolling InterestsTotal Shareholders’Investment
BALANCE AS OF JULY 1, 2025219,520,750$13,171,245$998,911,809$1,421,351,763$(3,396,649)$2,430,038,168$599,556$2,430,637,724
Issuance of common stock from stock plan transactions434,63426,0787,028,233——7,054,311—7,054,311
Repurchases of common stock(1,003,580)(60,215)(4,044,427)(24,178,827)—(28,283,469)—(28,283,469)
Stock-based compensation expense related to stock options, employee stock purchases and restricted stock——10,436,395——10,436,395—10,436,395
Dividends declared ($0.12 per share)———(26,274,216)—(26,274,216)—(26,274,216)
Purchase of additional interest in EyeLock LLC——525,301——525,301(600,301)(75,000)
Net income (1)———100,967,910—100,967,910745100,968,655
Other comprehensive income————750,426750,426—750,426
BALANCE AS OF SEPTEMBER 30, 2025218,951,804$13,137,108$1,012,857,311$1,471,866,630$(2,646,223)$2,495,214,826$—$2,495,214,826
BALANCE AS OF JULY 1, 2024230,229,539$13,813,772$1,000,014,813$1,394,446,595$(7,975,653)$2,400,299,527$—$2,400,299,527
Issuance of common stock from stock plan transactions408,56624,5143,757,530——3,782,044—3,782,044
Repurchases of common stock(3,194,815)(191,689)(12,363,936)(83,784,324)—(96,339,949)—(96,339,949)
Stock-based compensation expense related to stock options, employee stock purchases and restricted stock——9,540,105——9,540,105—9,540,105
Dividends declared ($0.12 per share)———(27,293,155)—(27,293,155)—(27,293,155)
Net income———122,549,041—122,549,041—122,549,041
Other comprehensive income————5,089,7295,089,729—5,089,729
BALANCE AS OF SEPTEMBER 30, 2024227,443,290$13,646,597$1,000,948,512$1,405,918,157$(2,885,924)$2,417,627,342$—$2,417,627,342

(1)Net income (loss) excludes net loss attributable to redeemable non-controlling interest of $81,902 for the three months ended September 30, 2025 (see Note 16).

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' INVESTMENT

For the Nine Months Ended September 30, 2025 and 2024

Common StockSharesCommon StockAmountAdditional Paid-InCapitalRetained EarningsAccumulated OtherComprehensiveLossTotalEquity Attributable to Noncontrolling InterestsTotal Shareholders’Investment
BALANCE AS OF JANUARY 1, 2025227,207,472$13,632,448$1,010,440,420$1,450,287,128$(6,409,341)$2,467,950,655$4,149,000$2,472,099,655
Issuance of common stock from stock plan transactions1,550,32793,02013,245,032——13,338,052—13,338,052
Repurchases of common stock(9,805,995)(588,360)(39,156,090)(190,706,233)—(230,450,683)—(230,450,683)
Stock-based compensation expense related to stock options, employee stock purchases and restricted stock——26,596,685——26,596,685—26,596,685
Dividends declared ($0.36 per share)———(79,595,804)—(79,595,804)—(79,595,804)
Capital contributions, net——————442,500442,500
Fair value of non-controlling interest in EyeLock LLC——————656,000656,000
Purchase of additional interest in EyeLock LLC——525,301——525,301(600,301)(75,000)
Purchase of additional interest in BioCenturion LLC——1,205,963——1,205,963(4,591,549)(3,385,586)
Net income (loss) (1)———291,881,539—291,881,539(55,650)291,825,889
Other comprehensive income————3,763,1183,763,118—3,763,118
BALANCE AS OF SEPTEMBER 30, 2025218,951,804$13,137,108$1,012,857,311$1,471,866,630$(2,646,223)$2,495,214,826$—$2,495,214,826
BALANCE AS OF JANUARY 1, 2024231,455,443$13,887,326$968,245,875$1,336,940,990$(6,557,122)$2,312,517,069$—$2,312,517,069
Issuance of common stock from stock plan transactions1,786,232107,17423,917,179——24,024,353—24,024,353
Repurchases of common stock(5,798,385)(347,903)(22,151,437)(165,179,271)—(187,678,611)—(187,678,611)
Stock-based compensation expense related to stock options, employee stock purchases and restricted stock——30,936,895——30,936,895—30,936,895
Dividends declared ($0.36 per share)———(82,663,756)—(82,663,756)—(82,663,756)
Net income———316,820,194—316,820,194—316,820,194
Other comprehensive income————3,671,1983,671,198—3,671,198
BALANCE AS OF SEPTEMBER 30, 2024227,443,290$13,646,597$1,000,948,512$1,405,918,157$(2,885,924)$2,417,627,342$—$2,417,627,342

(1)Net income (loss) excludes net loss attributable to redeemable non-controlling interest of $414,641 for the nine months ended September 30, 2025 (see Note 16).

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.